Mahesh Michael Umapathysivam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mahesh Michael Umapathysivam has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
David Jesudason
Freemason Centre for Men's Health and Wellbeing University of Adelaide Adelaide Australia
4 shared publications- Karen Louise Jones
School of Medicine, College of Health Adelaide University Adelaide Australia
4 shared publications - Michael Horowitz
Adelaide Medical School, University of Adelaide, Adelaide, Australia
4 shared publications Bethany Morgan
Endocrine Department, Queen Elizabeth Hospital, Woodville, South Australia, Australia
3 shared publications- Christopher K. Rayner
Centre of Research Excellence in Translating Nutritional Science to Good Health, Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia
3 shared publications - Ryan Joseph Jalleh
Endocrine and Metabolic Unit, Royal Adelaide Hospital , Adelaide, SA 5000
3 shared publications
Latest Publications
- 20 October 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (11) , 1941-1943
Toward Precision Prescribing of GLP-1 Receptor Agonists for Glucose Lowering
- 20 October 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (11) , 1941-1943
Toward Precision Prescribing of GLP-1 Receptor Agonists for Glucose Lowering
- 1 October 2026
- Published by American Physiological Society in Physiological Reviews
- Vol. 106 (4) , 2317-2382
Impact of gastric emptying and small intestinal carbohydrate absorption on glycemia in health and diabetes: therapeutic implications
Gastric emptying, which exhibits a substantial interindividual, but much lesser intraindividual, variation in health and is frequently disordered (particularly delayed) in diabetes, is now appreciated to be a major determinant of postprandial glycemia. The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted in the proximal and distal small intestine, respectively, in response to nutrients. GLP-1, together with peptide tyrosine-tyrosine (PYY), stimulates potent negative feedback on gastric emptying. Modulation of gastric emptying, through dietary, pharmacologic, and surgical therapies, has been utilized in current clinical practice for the treatment of hyperglycemia, particularly relating to type 2 diabetes. We review the complex, interdependent relationships between gastric emptying, small intestinal transit, glucose absorption, neurohormonal regulatory responses, and postprandial glycemia. We discuss how this has informed fundamental advances in the understanding and rational management of obesity, stress hyperglycemia, type 1 and 2 diabetes, and gestational diabetes, and we provide recommendations for research priorities that have the potential to impact practice. We also discuss the frequent complication of abnormally delayed gastric emptying (gastroparesis) in both type 1 and type 2 diabetes, the implications for management of diabetes, and the impact of treatment on gastric emptying. With the increasing recognition of the importance of gastric emptying in the management of conditions associated with disordered glucose metabolism, and the advent and increasing use of GLP-1 receptor agonists, an improved definition of the interactions between gastrointestinal motility (gastric emptying and small intestinal transit) and enteropancreatic hormonal responses is essential.
- 1 October 2026
- Published by American Physiological Society in Physiological Reviews
- Vol. 106 (4) , 2317-2382
Impact of gastric emptying and small intestinal carbohydrate absorption on glycemia in health and diabetes: therapeutic implications
Gastric emptying, which exhibits a substantial interindividual, but much lesser intraindividual, variation in health and is frequently disordered (particularly delayed) in diabetes, is now appreciated to be a major determinant of postprandial glycemia. The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted in the proximal and distal small intestine, respectively, in response to nutrients. GLP-1, together with peptide tyrosine-tyrosine (PYY), stimulates potent negative feedback on gastric emptying. Modulation of gastric emptying, through dietary, pharmacologic, and surgical therapies, has been utilized in current clinical practice for the treatment of hyperglycemia, particularly relating to type 2 diabetes. We review the complex, interdependent relationships between gastric emptying, small intestinal transit, glucose absorption, neurohormonal regulatory responses, and postprandial glycemia. We discuss how this has informed fundamental advances in the understanding and rational management of obesity, stress hyperglycemia, type 1 and 2 diabetes, and gestational diabetes, and we provide recommendations for research priorities that have the potential to impact practice. We also discuss the frequent complication of abnormally delayed gastric emptying (gastroparesis) in both type 1 and type 2 diabetes, the implications for management of diabetes, and the impact of treatment on gastric emptying. With the increasing recognition of the importance of gastric emptying in the management of conditions associated with disordered glucose metabolism, and the advent and increasing use of GLP-1 receptor agonists, an improved definition of the interactions between gastrointestinal motility (gastric emptying and small intestinal transit) and enteropancreatic hormonal responses is essential.
- Open Access
- 8 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11986-11989
Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes
- 8 September 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11986-11989
Open AccessGlucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes
- Open Access
- 25 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 6959-6964
Higher Serum Testosterone Protects Against the Development of Type 2 Diabetes in Middle‐Aged but Not Older Men
Background: Low serum testosterone concentration has been reported to be causally linked to the risk of Type 2 diabetes (T2D). The benefit of T2D protection has been demonstrated to continue up to serum testosterone concentrations of 461 ng/dL (16 nmol/L). It is unclear if there is an upper threshold for this effect of testosterone nor whether this causal process is moderated by age, waist circumference (WC) or baseline glycaemia (A1c). Aim: To examine the effect of WC, age and baseline glycaemia on the relationship between testosterone and incident T2D risk. Methods: Men without T2D, cancer or testosterone treatment and with baseline and 5‐year follow‐up assessments in the Men Androgen Inflammation Lifestyle and Environment Study cohort were included. The association between baseline testosterone and 5‐year incident T2D was assessed using confounder‐adjusted logistic regressions, with and without restricted cubic splines and pairwise interactions with age, WC and baseline A1c. Primary analyses were in the complete case set, with multiple imputation being performed as a sensitivity analysis. Results: The analysis included 1299 men with 109 cases of 5‐year incident T2D (8.4%). An independent inverse relationship between serum testosterone concentration and 5‐year incident T2D was observed (OR = 0.92, 95% CI = [0.87, 0.97], p = 0.001). There were no detectable interactions between testosterone and either WC ( p = 0.93) or baseline A1c ( p = 0.38). There was, however, evidence for a strong interaction between testosterone and age ( p = 0.003), with low testosterone being associated with elevated T2D risk only in younger men. Conclusions: These data suggest that higher concentrations of serum testosterone are protective against incident T2D in younger but not older men.
- 25 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 6959-6964
Open AccessHigher Serum Testosterone Protects Against the Development of Type 2 Diabetes in Middle‐Aged but Not Older Men
Background: Low serum testosterone concentration has been reported to be causally linked to the risk of Type 2 diabetes (T2D). The benefit of T2D protection has been demonstrated to continue up to serum testosterone concentrations of 461 ng/dL (16 nmol/L). It is unclear if there is an upper threshold for this effect of testosterone nor whether this causal process is moderated by age, waist circumference (WC) or baseline glycaemia (A1c). Aim: To examine the effect of WC, age and baseline glycaemia on the relationship between testosterone and incident T2D risk. Methods: Men without T2D, cancer or testosterone treatment and with baseline and 5‐year follow‐up assessments in the Men Androgen Inflammation Lifestyle and Environment Study cohort were included. The association between baseline testosterone and 5‐year incident T2D was assessed using confounder‐adjusted logistic regressions, with and without restricted cubic splines and pairwise interactions with age, WC and baseline A1c. Primary analyses were in the complete case set, with multiple imputation being performed as a sensitivity analysis. Results: The analysis included 1299 men with 109 cases of 5‐year incident T2D (8.4%). An independent inverse relationship between serum testosterone concentration and 5‐year incident T2D was observed (OR = 0.92, 95% CI = [0.87, 0.97], p = 0.001). There were no detectable interactions between testosterone and either WC ( p = 0.93) or baseline A1c ( p = 0.38). There was, however, evidence for a strong interaction between testosterone and age ( p = 0.003), with low testosterone being associated with elevated T2D risk only in younger men. Conclusions: These data suggest that higher concentrations of serum testosterone are protective against incident T2D in younger but not older men.
- Open Access
- 20 April 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 236, 113274
Continuous glucose monitoring for cystic fibrosis-related diabetes: impact on quality of life and glycaemic control
- 20 April 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 236, 113274
Open AccessContinuous glucose monitoring for cystic fibrosis-related diabetes: impact on quality of life and glycaemic control
- Top Cited PapersOpen Access
- 17 October 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (1) , 1-15
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Context: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This helps to limit postprandial glycemic excursions and reduce chylomicron formation and triglyceride absorption. Conversely, motility effects may have detrimental consequences, eg, retained gastric contents at endoscopy or general anesthesia, potentially complicated by pulmonary aspiration or bowel obstruction. Data Acquisition: We searched the PubMed database for studies involving GLP-1RA therapy and adverse gastrointestinal/biliary events. Data Synthesis: Retained gastric contents at the time of upper gastrointestinal endoscopy are found more frequently with GLP-1 RAs but rarely are associated with pulmonary aspiration. Well-justified recommendations for the periprocedural management of GLP-1RAs (eg, whether to withhold these medications and for how long) are compromised by limited evidence. Important aspects to be considered are (1) their long half-lives, (2) the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological GLP-1 concentrations, (c) tachyphylaxis observed with prolonged treatment, and (d) the limited effect on gastric emptying in individuals with slow gastric emptying before initiating treatment. Little information is available on the influence of diabetes mellitus itself (ie, in the absence of GLP-1 RA treatment) on retained gastric contents and pulmonary aspiration. Conclusion: Prolonged fasting periods regarding solid meal components, point-of-care ultrasound examination for retained gastric content, and the use of prokinetic medications like erythromycin may prove helpful and represent an important area needing further study to increase patient safety for those treated with GLP-1 RAs.
- 17 October 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (1) , 1-15
Top Cited PapersOpen AccessClinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Context: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This helps to limit postprandial glycemic excursions and reduce chylomicron formation and triglyceride absorption. Conversely, motility effects may have detrimental consequences, eg, retained gastric contents at endoscopy or general anesthesia, potentially complicated by pulmonary aspiration or bowel obstruction. Data Acquisition: We searched the PubMed database for studies involving GLP-1RA therapy and adverse gastrointestinal/biliary events. Data Synthesis: Retained gastric contents at the time of upper gastrointestinal endoscopy are found more frequently with GLP-1 RAs but rarely are associated with pulmonary aspiration. Well-justified recommendations for the periprocedural management of GLP-1RAs (eg, whether to withhold these medications and for how long) are compromised by limited evidence. Important aspects to be considered are (1) their long half-lives, (2) the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological GLP-1 concentrations, (c) tachyphylaxis observed with prolonged treatment, and (d) the limited effect on gastric emptying in individuals with slow gastric emptying before initiating treatment. Little information is available on the influence of diabetes mellitus itself (ie, in the absence of GLP-1 RA treatment) on retained gastric contents and pulmonary aspiration. Conclusion: Prolonged fasting periods regarding solid meal components, point-of-care ultrasound examination for retained gastric content, and the use of prokinetic medications like erythromycin may prove helpful and represent an important area needing further study to increase patient safety for those treated with GLP-1 RAs.
- Open Access
- 1 October 2024
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2024 (4)
Propofol-induced transient arginine vasopressin deficiency
Summary: We describe and characterise the case of a 26-year-old female undergoing surgery for a right-sided sinonasal alveolar rhabdomyosarcoma who developed profound, transient arginine vasopressin deficiency (AVP-D, formerly central diabetes insipidus (DI)) associated with anaesthesia. In this case report, we characterise the development of AVP-D with serial copeptin and paired urine and serum osmolality measurements. Based on the anaesthetic agent’s profile and the literature, we attribute this presentation to propofol exposure. We present a description of the literature on anaesthesia-associated DI as well as poignant learning points. Learning points: Exposure to anaesthetic agents is a rare cause of self-limited but sudden and profound arginine vasopressin deficiency (AVP-D) or arginine vasopressin resistance (AVP-R). Sevoflurane has been associated with AVP-R and propofol with AVP-D, although the responsible agent may be difficult to identify. Differentiation of AVP-R and AVP-D can be made based on copeptin concentration, where available, or clinical response to desmopressin. Whilst the patient is anaesthetised, intravenous fluid replacement should be targeted to match urine output until the patient is able to drink to thirst. This should be clearly communicated to staff and the patient. Rapid resolution of AVP-R/AVP-D when the causative agent is discontinued has been reported with both propofol and sevoflurane. As such, switching the agent used to maintain anaesthesia may terminate increased urine output in a clinically meaningful timeframe.
- 1 October 2024
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2024 (4)
Open AccessPropofol-induced transient arginine vasopressin deficiency
Summary: We describe and characterise the case of a 26-year-old female undergoing surgery for a right-sided sinonasal alveolar rhabdomyosarcoma who developed profound, transient arginine vasopressin deficiency (AVP-D, formerly central diabetes insipidus (DI)) associated with anaesthesia. In this case report, we characterise the development of AVP-D with serial copeptin and paired urine and serum osmolality measurements. Based on the anaesthetic agent’s profile and the literature, we attribute this presentation to propofol exposure. We present a description of the literature on anaesthesia-associated DI as well as poignant learning points. Learning points: Exposure to anaesthetic agents is a rare cause of self-limited but sudden and profound arginine vasopressin deficiency (AVP-D) or arginine vasopressin resistance (AVP-R). Sevoflurane has been associated with AVP-R and propofol with AVP-D, although the responsible agent may be difficult to identify. Differentiation of AVP-R and AVP-D can be made based on copeptin concentration, where available, or clinical response to desmopressin. Whilst the patient is anaesthetised, intravenous fluid replacement should be targeted to match urine output until the patient is able to drink to thirst. This should be clearly communicated to staff and the patient. Rapid resolution of AVP-R/AVP-D when the causative agent is discontinued has been reported with both propofol and sevoflurane. As such, switching the agent used to maintain anaesthesia may terminate increased urine output in a clinically meaningful timeframe.
- Open Access
- 4 March 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (3) , e242744
SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis
The pathophysiology of sodium-glucose cotransporter 2 inhibitor (SGLT2i)–associated ketoacidosis (DKA) differs from type 1 diabetes (T1D) DKA. T1D DKA is driven by absolute insulin deficiency, leading to ketosis and hyperglycemia. In contrast, SGLT2i DKA occurs due to reduction in plasma glucose (PG) from urinary glucose losses, which reduces insulin secretion and stimulates glucagon secretion, leading to ketosis.1-3 Accordingly, PG levels in SGLT2i DKA are often normal or mildly elevated.2,3 The implication is that glycemia and ketosis are less closely linked than in T1D DKA. Despite these differences, the American Association of Clinical Endocrinologists and American College of Endocrinology recommends treatment with the same protocols as T1D.4 This may result in hypoglycemia when patients receive fixed-dose insulin infusion or inadequate insulin dosing and reduced ketone clearance when patients receive dynamic insulin infusions.
- 4 March 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (3) , e242744
Open AccessSGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis
The pathophysiology of sodium-glucose cotransporter 2 inhibitor (SGLT2i)–associated ketoacidosis (DKA) differs from type 1 diabetes (T1D) DKA. T1D DKA is driven by absolute insulin deficiency, leading to ketosis and hyperglycemia. In contrast, SGLT2i DKA occurs due to reduction in plasma glucose (PG) from urinary glucose losses, which reduces insulin secretion and stimulates glucagon secretion, leading to ketosis.1-3 Accordingly, PG levels in SGLT2i DKA are often normal or mildly elevated.2,3 The implication is that glycemia and ketosis are less closely linked than in T1D DKA. Despite these differences, the American Association of Clinical Endocrinologists and American College of Endocrinology recommends treatment with the same protocols as T1D.4 This may result in hypoglycemia when patients receive fixed-dose insulin infusion or inadequate insulin dosing and reduced ketone clearance when patients receive dynamic insulin infusions.
- Open Access
- 21 November 2023
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (1) , 140-143
Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction
OBJECTIVE: Ketoacidosis induced by sodium–glucose cotransporter 2 inhibitor (SGLT2i) treatment has been consistently observed in clinical practice in patients with type 2 diabetes despite minimal indication from the landmark cardiovascular outcome trials. It has been postulated that individuals without diabetes will not develop this complication due to an adequate insulin secretory capacity, which will protect against significant ketone formation. Cardiovascular outcome trials examining SGLT2i use in individuals with heart failure but not diabetes have not reported ketoacidosis. RESEARCH DESIGN AND METHODS: We describe the first two case reports of severe nondiabetic ketoacidosis after initiation of an SGLT2i for the treatment of heart failure with reduced ejection fraction, and we describe the management strategies employed and implication for the pathophysiology of SGLT2i-associated ketoacidosis. RESULTS: Each individual presented with ketoacidosis triggered by reduced oral nutrition intake. For both individuals, ketoacidosis resolved with intravenous glucose administration, encouragement of consumption of oral glucose-containing fluid, and minimal insulin administration. CONCLUSIONS: These two cases demonstrate that SGLT2i-associated ketoacidosis is possible in individuals without diabetes.
- 21 November 2023
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (1) , 140-143
Open AccessEuglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction
OBJECTIVE: Ketoacidosis induced by sodium–glucose cotransporter 2 inhibitor (SGLT2i) treatment has been consistently observed in clinical practice in patients with type 2 diabetes despite minimal indication from the landmark cardiovascular outcome trials. It has been postulated that individuals without diabetes will not develop this complication due to an adequate insulin secretory capacity, which will protect against significant ketone formation. Cardiovascular outcome trials examining SGLT2i use in individuals with heart failure but not diabetes have not reported ketoacidosis. RESEARCH DESIGN AND METHODS: We describe the first two case reports of severe nondiabetic ketoacidosis after initiation of an SGLT2i for the treatment of heart failure with reduced ejection fraction, and we describe the management strategies employed and implication for the pathophysiology of SGLT2i-associated ketoacidosis. RESULTS: Each individual presented with ketoacidosis triggered by reduced oral nutrition intake. For both individuals, ketoacidosis resolved with intravenous glucose administration, encouragement of consumption of oral glucose-containing fluid, and minimal insulin administration. CONCLUSIONS: These two cases demonstrate that SGLT2i-associated ketoacidosis is possible in individuals without diabetes.
- Open Access
- 30 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (2) , e809-e816
Approach to the Patient: Reninoma
A reninoma is a functional tumor of afferent arteriolar juxtaglomerular cells that secretes the enzyme renin, leading to hyperactivation of the renin-angiotensin-aldosterone system. Reninoma is a potentially curable cause of pathological secondary hyperaldosteronism that results in often severe hypertension and hypokalemia. The lack of suppression of plasma renin contrasts sharply with the much more common primary aldosteronism, but diagnosis is often prompted by screening for that condition. The major differential diagnosis of reninoma is renovascular hypertension. Fewer than 200 cases of reninoma have been described. Reninomas have been reported across a broad demographic but have a 2:1 predilection for women, often of childbearing age. Aldosterone receptor blockade, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers offer effective medical management but are contraindicated in pregnancy, so surgical curative resection is ideal. The current optimal imaging and biochemical workup of reninoma and management approach (ideally, tumor excision with subtotal renal resection) are described.
- 30 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (2) , e809-e816
Open AccessApproach to the Patient: Reninoma
A reninoma is a functional tumor of afferent arteriolar juxtaglomerular cells that secretes the enzyme renin, leading to hyperactivation of the renin-angiotensin-aldosterone system. Reninoma is a potentially curable cause of pathological secondary hyperaldosteronism that results in often severe hypertension and hypokalemia. The lack of suppression of plasma renin contrasts sharply with the much more common primary aldosteronism, but diagnosis is often prompted by screening for that condition. The major differential diagnosis of reninoma is renovascular hypertension. Fewer than 200 cases of reninoma have been described. Reninomas have been reported across a broad demographic but have a 2:1 predilection for women, often of childbearing age. Aldosterone receptor blockade, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers offer effective medical management but are contraindicated in pregnancy, so surgical curative resection is ideal. The current optimal imaging and biochemical workup of reninoma and management approach (ideally, tumor excision with subtotal renal resection) are described.